133 related articles for article (PubMed ID: 34254292)
1. Parkinson's disease in Sweden-resource use and costs by severity.
Hjalte F; Norlin JM; Kellerborg K; Odin P
Acta Neurol Scand; 2021 Nov; 144(5):592-599. PubMed ID: 34254292
[TBL] [Abstract][Full Text] [Related]
2. Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study.
M Norlin J; Hjalte F; Kruse C; Dodel R; Rosqvist K; Odin P
Acta Neurol Scand; 2022 Jun; 145(6):743-752. PubMed ID: 35312034
[TBL] [Abstract][Full Text] [Related]
3. Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
Hagell P; Nordling S; Reimer J; Grabowski M; Persson U
Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059
[TBL] [Abstract][Full Text] [Related]
4. Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.
Norlin JM; Kellerborg K; Odin P
Pharmacoeconomics; 2021 Oct; 39(10):1141-1149. PubMed ID: 34231134
[TBL] [Abstract][Full Text] [Related]
5. Drug and treatment costs in Parkinson's disease patients in Sweden.
Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
[TBL] [Abstract][Full Text] [Related]
6. Trends in resource utilization for Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
[TBL] [Abstract][Full Text] [Related]
7. Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
Kruse C; Lipinski A; Verheyen M; Balzer-Geldsetzer M; Wittenberg M; Lorenzl S; Richinger C; Schmotz C; Tönges L; Woitalla D; Klebe S; Bloem BR; Hommel A; Meissner WG; Laurens B; Boraud T; Foubert-Samier A; Vergnet S; Tison F; Costa N; Odin P; Rosqvist K; Norlin JM; Hjalte F; Schrag A; Dodel R
Mov Disord; 2024 Mar; 39(3):571-584. PubMed ID: 38425158
[TBL] [Abstract][Full Text] [Related]
8. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
9. Health economic costs of COPD in Sweden by disease severity--has it changed during a ten years period?
Jansson SA; Backman H; Stenling A; Lindberg A; Rönmark E; Lundbäck B
Respir Med; 2013 Dec; 107(12):1931-8. PubMed ID: 23910072
[TBL] [Abstract][Full Text] [Related]
10. Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study.
Kruse C; Kretschmer S; Lipinski A; Verheyen M; Mengel D; Balzer-Geldsetzer M; Lorenzl S; Richinger C; Schmotz C; Tönges L; Woitalla D; Klebe S; Schrag A; Dodel R
Pharmacoeconomics; 2021 May; 39(5):601-615. PubMed ID: 33738776
[TBL] [Abstract][Full Text] [Related]
11. Costs of coronary heart disease and stroke: the case of Sweden.
Zethraeus N; Molin T; Henriksson P; Jönsson B
J Intern Med; 1999 Aug; 246(2):151-9. PubMed ID: 10447784
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between PDQ-8 and Costs in Parkinson's Disease-A Swedish Register-Based Study.
Kellerborg K; Norlin JM; Odin P
Mov Disord Clin Pract; 2023 Feb; 10(2):231-237. PubMed ID: 36825055
[TBL] [Abstract][Full Text] [Related]
13. The economic consequences of asthma among adults in Sweden.
Jansson SA; Rönmark E; Forsberg B; Löfgren C; Lindberg A; Lundbäck B
Respir Med; 2007 Nov; 101(11):2263-70. PubMed ID: 17689234
[TBL] [Abstract][Full Text] [Related]
14. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of prostate cancer - a Swedish prevalence-based register study.
Hao S; Östensson E; Eklund M; Grönberg H; Nordström T; Heintz E; Clements M
BMC Health Serv Res; 2020 May; 20(1):448. PubMed ID: 32434566
[TBL] [Abstract][Full Text] [Related]
16. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
Weir S; Samnaliev M; Kuo TC; Tierney TS; Walleser Autiero S; Taylor RS; Schrag A
Mov Disord; 2018 Jul; 33(6):974-981. PubMed ID: 29603405
[TBL] [Abstract][Full Text] [Related]
18. Cost of Parkinson's disease among Filipino patients seen at a public tertiary hospital in Metro Manila.
Prado M; Jamora RD
J Clin Neurosci; 2020 Apr; 74():41-46. PubMed ID: 31983646
[TBL] [Abstract][Full Text] [Related]
19. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia.
Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L
J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991
[TBL] [Abstract][Full Text] [Related]
20. [Cost of illness and health service patterns in Morbus Parkinson in Austria].
von Campenhausen S; Winter Y; Gasser J; Seppi K; Reese JP; Pfeiffer KP; Geiger-Gritsch S; Bötzel K; Siebert U; Oertel WH; Dodel R; Poewe W
Wien Klin Wochenschr; 2009; 121(17-18):574-82. PubMed ID: 19890747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
